Pfizer is committed to helping people with chronic inflammatory diseases—alopecia areata (AA), atopic dermatitis (AD), psoriatic arthritis (PsA), rheumatoid arthritis (RA), ulcerative colitis (UC), and ankylosing spondylitis (AS)—become empowered to play an important role in managing their medical condition with their doctor.
The Personal Empowerment Portal offers a wide range of print and digital materials to support patients in this process.
Educational content on the Personal Empowerment Portal is designed to help patients partner with their medical team in shared decision-making about personal treatment-related issues and options. Materials are available in English and Spanish.
Patients and healthcare professionals (HCPs) will be able to access print and digital educational materials about AA, AD, PsA, RA, UC, and AS.
In summary, the Personal Empowerment Portal delivers resources for patients to support shared decision-making and communication with their physician.
Self-assessment tools, application instructions, and action plan forms to help patients identify ways to work with their HCPs in managing AD
Insights on the principal goals of PsA treatment — along with questionnaires and information-gathering tools — to help patients work with rheumatologists, dermatologists, pharmacists and other HCPs to support treatment
Diaries, questionnaires, and self-assessment tools that monitor UC-related symptoms — including stool frequency and rectal bleeding-as well as other potential signs and symptoms, such as fatigue and lifestyle changes
Clinical information about AS, including its signs, symptoms, and some medications that may be used to treat it
Management approaches and core goals of treatment in AS
The health information in this site is provided for educational purposes only and is not intended to replace discussions with a healthcare provider.
All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.
This site is intended only for US residents.
2025 Pfizer Inc. All rights reserved.